|
Recent Developments |
|
05-DEC-18
Alembic Pharmaceuticals today announced that the company has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Candesartan Cilexetil Tablets USP, 4 mg, 8 mg, and 16 mg.
28-NOV-18
Alembic Pharmaceuticals announced that it has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Temazepam Capsules USP 7.5mg, 15mg,... More.. |
| Business Profile |
Future Plans |
|
|
|
|
One To One
|
|
Recent news
|
|
|
| Brief Financials (in Rs. Mn.) | |
| Period ending (months) | 30-Jun-2021(3) | 31-Mar-2021 (12) | 31-Mar-2020 (12) | | Net sales | 12696.91 | 50514.40 | 41325.52 | | Other Income | 17.39 | 97.30 | 1347.54 | | Total Income | 12714.30 | 50611.70 | 42673.06 | | Cost of goods sold | -10382.38 | -36445.80 | -30905.14 | | OPBDIT | 23096.68 | 87057.50 | 73578.20 | | PAT | 1926.94 | 11753.90 | 9694.05 | | Gross Block | - | - | - | | Equity capital | - | 0.00 | 0.00 | | EPS (Rs.) | - | 0.00 | 0.00 | | DPS (Rs.) | - | - | - | | BV (Rs.) | - | - | - | | P/E range (x) | - | NA | NA | | Debt / Equity (x) | - | - | - | | Operating margin (% of OI) | 181.7 | 172.0 | 172.4 | | Net margin (% of OI) | 15.2 | 23.2 | 22.7 |
|
|
Detailed Financials
|
|
|
|
|
